PHAT News and Press, Phathom Pharmaceuticals Inc. From 11/08/21

Two New Drug Applications (NDAs) for vonoprazan-based treatment regimens for H. pylori infection were accepted for filing by FDA with six-month Priority Review granted; PDUFA target action date of May 3, 2022 U.S. launch for both vonoprazan-based treatment regimens for H. py...

Phathom Pharmaceuticals (NASDAQ:PHAT) shares rise more than 10% premarket after the company announced the withdrawal of its previously announced primary and secondary public offering. The company had cash and cash equivalents of $225M as of September 30, 2021. Phathom expects c...

FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the withdrawal of the previously...

Gainers: Siyata Mobile (NASDAQ:SYTA) +179%. AgriFORCE (NASDAQ:AGRI) +180%. China XD Plastics (NASDAQ:CXDC) +70%. Pasithea (NASDAQ:KTTA) +46%. Enphase (NASDAQ:ENPH) +28%. Kaival Brands (NASDAQ:KAVL) +25%. Leju Holdings (NYSE:LEJU) +24%. Volcon (NASDAQ:VLCN) +22%. Nurix (NASDAQ:NRIX) +22%. Guar...

FLORHAM PARK, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today an underwritten public offering of 5,...

Data from Phase 3 PHALCON-HP trial highlighted in oral presentation and recognized with the ACG Governors Award for Excellence in Clinical Research Phase 1 population PK data abstract concludes the large body of pre-existing clinical data related to vonoprazan in Asian populations...

FLORHAM PARK, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that data for vonoprazan, an investig...

Gainers: ION Geophysical (NYSE:IO) +42%. Valneva (NASDAQ:VALN) +33%. Progenity (NASDAQ:PROG) +31%. MeiraGTx (NASDAQ:MGTX) +30%. BTCS (NASDAQ:BTCS) +22%. Peabody Energy (NYSE:BTU) +20%. Evolving Systems (NASDAQ:EVOL) +18%. InMed (NASDAQ:INM) +16%. TORM (NASDAQ:TRMD) +17%. Aerovate (NASDAQ:AVTE...

Gainers: Valneva SE VALN +33%, MeiraGTx (NASDAQ:MGTX) +22%, Adamis Pharmaceuticals ADMP +20%, Aerovate Therapeutics AVTE +18%, Progenity (NASDAQ:PROG) +16%. Losers: Revance Therapeutics RVNC -42%, Omeros OMER -25%, MannKind MNKD...

Vonoprazan met its primary non-inferiority endpoints in both healing and maintenance phases Vonoprazan demonstrated superior healing rates in patients with moderate-to-severe disease at Week 2 versus lansoprazole (PREVACID ® ), a proton pump inhibitor (PPI) Vonopr...